Biotech

Theralase Technologies announced it demonstrated increased efficacy from their anti-cancer drug TLD-1633 compared to its lead anti-cancer drug TLD-1433.

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced it demonstrated increased efficacy from their anti-cancer drug TLD-1633 compared to its lead anti-cancer drug TLD-1433.
As quoted in the press release:

The latest PDC, known as TLD-1633, has recently been shown to be approximately 15% more effective than TLD-1433 in the destruction of a human Glioblastoma Multiforme (“GBM“) cell line (U87), a deadly form of brain cancer.
In preclinical research, TLD-1633 has also demonstrated a lower dark toxicity, supporting an even higher safety profile than TLD-1433.
Pavel Kaspler, Ph.D., a research scientist at Theralase, stated that, “Research on Theralase’s latest licensed anti-cancer drug, TLD-1633, is showing even stronger data preclinically than Theralase’s top performing anti-cancer drug TLD-1433. I look forward to expanding my research to assess the performance of TLD-1633 in various cancer lines, with and without the use of transferrin, as a transport system.”

Click here to read the full press release.

Source: www.accesswire.com

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×